WNK2 and cancer: Second, we tested the efficacies of an mTOR inhibitor (Torin 1), a mitogen-activated protein kinase (MAPK) inhibitor (PD98059) and a neutralizing antibody against E-cadherin on cancer cells in BICA, IVBL or 2D cultures.